We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 5, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , Danaher Corp. (DHR - Free Report) , Citigroup Inc. (C - Free Report) , Shopify Inc. (SHOP - Free Report) and Canadian Pacific Kansas City Ltd. (CP - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Eli Lilly, Danaher and Citigroup
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., Danaher Corp. and Citigroup Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+96.7% vs. +25.7%). The company’s revenue growth is being driven by higher demand for drugs like Verzenio, Trulicity, Taltz and others. Sales of its new drug, Mounjaro, are benefiting from strong demand trends.
Lilly is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer’s disease. Mounjaro was recently approved for the obesity indication by the name of Zepbound. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly. The company has also gained approvals for some other new drugs in 2023.
However, generic competition for some drugs, rising pricing pressure and challenges in meeting strong demand for incretin products are some top-line headwinds. Estimates have declined slightly ahead of Q4 results. Lilly has a mixed record of earnings surprises in the recent quarters.
Shares of Danaher have outperformed the Zacks Diversified Operations industry over the past year (+3.3% vs. +2.4%). Stable demand in the academic and life science research markets is supporting Danaher’s Life Sciences segment. In the segment, the company has been witnessing positive responses toward its new products.
Its commitment to return value to shareholders is encouraging. Synergies from the Abcam acquisition bolster the company’s growth. Through its DBS initiatives, it has been able to reduce the impact of supply-chain constraints and inflationary pressures.
However, Danaher is plagued by weakness in the Biotechnology and Diagnostics segments due to a decrease in the sale of COVID-related products. The slowdown in the pharma and biopharma markets is an added concern. High debt levels, if not controlled, might raise the company's financial obligations and drain its profitability. Given its international exposure, forex woes are weighing on its top line.
Citigroup’s shares have outperformed the Zacks Banks - Major Regional industry over the past year (+13.9% vs. +6.3%). The company’s fourth-quarter results witnessed growth in total loans and deposits. It is undergoing an organizational overhaul, which is expected to simplify operations.
The company remains on track to exit the consumer banking business in international markets and focus on growth in wealth management and commercial banking.
High interest rates will continue to aid net interest income (NII), though rising funding costs will weigh on it. However, escalating expenses will likely limit bottom-line growth. Fee income volatility remains a major headwind.
Other noteworthy reports we are featuring today include Shopify Inc. and Canadian Pacific Kansas City Ltd.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Eli Lilly, Danaher, Citigroup, Shopify and Canadian Pacific Kansas
For Immediate Release
Chicago, IL – February 5, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , Danaher Corp. (DHR - Free Report) , Citigroup Inc. (C - Free Report) , Shopify Inc. (SHOP - Free Report) and Canadian Pacific Kansas City Ltd. (CP - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Eli Lilly, Danaher and Citigroup
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., Danaher Corp. and Citigroup Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+96.7% vs. +25.7%). The company’s revenue growth is being driven by higher demand for drugs like Verzenio, Trulicity, Taltz and others. Sales of its new drug, Mounjaro, are benefiting from strong demand trends.
Lilly is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer’s disease. Mounjaro was recently approved for the obesity indication by the name of Zepbound. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly. The company has also gained approvals for some other new drugs in 2023.
However, generic competition for some drugs, rising pricing pressure and challenges in meeting strong demand for incretin products are some top-line headwinds. Estimates have declined slightly ahead of Q4 results. Lilly has a mixed record of earnings surprises in the recent quarters.
(You can read the full research report on Eli Lilly here >>>)
Shares of Danaher have outperformed the Zacks Diversified Operations industry over the past year (+3.3% vs. +2.4%). Stable demand in the academic and life science research markets is supporting Danaher’s Life Sciences segment. In the segment, the company has been witnessing positive responses toward its new products.
Its commitment to return value to shareholders is encouraging. Synergies from the Abcam acquisition bolster the company’s growth. Through its DBS initiatives, it has been able to reduce the impact of supply-chain constraints and inflationary pressures.
However, Danaher is plagued by weakness in the Biotechnology and Diagnostics segments due to a decrease in the sale of COVID-related products. The slowdown in the pharma and biopharma markets is an added concern. High debt levels, if not controlled, might raise the company's financial obligations and drain its profitability. Given its international exposure, forex woes are weighing on its top line.
(You canread the full research report on Danaher here >>>)
Citigroup’s shares have outperformed the Zacks Banks - Major Regional industry over the past year (+13.9% vs. +6.3%). The company’s fourth-quarter results witnessed growth in total loans and deposits. It is undergoing an organizational overhaul, which is expected to simplify operations.
The company remains on track to exit the consumer banking business in international markets and focus on growth in wealth management and commercial banking.
High interest rates will continue to aid net interest income (NII), though rising funding costs will weigh on it. However, escalating expenses will likely limit bottom-line growth. Fee income volatility remains a major headwind.
(You can read the full research report on Citigroup here >>>)
Other noteworthy reports we are featuring today include Shopify Inc. and Canadian Pacific Kansas City Ltd.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.